Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764198 in focal segmental glomerulosclerosis
2024-511706-23-00Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing BI 764198 with Placebo (2 arms). Primary endpoint: Number of patients achieving at least 25% reduction in 24-hour urine protein-creatinine ratio (UPCR) relative to baseline at week 12. Started May 2022; status: completed.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2024-511706-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511706-23-00.